{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:47:01Z","timestamp":1791586021915,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1245\/s10434-026-19739-2","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T15:54:16Z","timestamp":1777737256000},"page":"9335-9343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer?"],"prefix":"10.1245","volume":"33","author":[{"given":"Dillon C.","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee-Chee","family":"Stucky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Egbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Asher","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Fu Jeffrey","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra L.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C.","family":"Linderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Bold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Wasif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6398-413X","authenticated-orcid":false,"given":"Zhi Ven","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"19739_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.21037\/jgo-24-213","volume":"15","author":"JY Tan","year":"2024","unstructured":"Tan JY, Yeo YH, Ng WL, et al. Pancreatic cancer mortality trends in the United States: how much have we moved the needle? J Gastrointest Oncol. 2024;15:1789\u201395.","journal-title":"J Gastrointest Oncol."},{"key":"19739_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326:851\u201362.","journal-title":"JAMA."},{"key":"19739_CR3","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1056\/NEJMra1404198","volume":"371","author":"DP Ryan","year":"2014","unstructured":"Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039\u201349.","journal-title":"N Engl J Med."},{"key":"19739_CR4","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1200\/JCO.19.00946","volume":"37","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol. 2019;37:2082\u20138.","journal-title":"J Clin Oncol."},{"key":"19739_CR5","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","volume":"8","author":"T Conroy","year":"2022","unstructured":"Conroy T, Castan F, Lopez A, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 2022;8:1571\u20138.","journal-title":"JAMA Oncol."},{"key":"19739_CR6","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1200\/JCO.22.01134","volume":"41","author":"MA Tempero","year":"2023","unstructured":"Tempero MA, Pelzer U, O\u2019Reilly EM, et al. Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J Clin Oncol. 2023;41:2007\u201319.","journal-title":"J Clin Oncol."},{"key":"19739_CR7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011\u201324.","journal-title":"Lancet."},{"key":"19739_CR8","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med."},{"key":"19739_CR9","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40:1220\u201330.","journal-title":"J Clin Oncol."},{"key":"19739_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/SLA.0000000000000378","volume":"260","author":"RP Merkow","year":"2014","unstructured":"Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260:372\u20137.","journal-title":"Ann Surg."},{"key":"19739_CR11","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1245\/s10434-024-14951-4","volume":"31","author":"S Paiella","year":"2024","unstructured":"Paiella S, Malleo G, Lionetto G, et al. Adjuvant therapy after upfront resection of resectable pancreatic cancer: patterns of omission and use-a prospective real-life study. Ann Surg Oncol. 2024;31:2892\u2013901.","journal-title":"Ann Surg Oncol."},{"key":"19739_CR12","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1245\/s10434-014-3722-6","volume":"21","author":"W Wu","year":"2014","unstructured":"Wu W, He J, Cameron JL, et al. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol. 2014;21:2873\u201381.","journal-title":"Ann Surg Oncol."},{"key":"19739_CR13","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1007\/s11605-018-3939-y","volume":"23","author":"M Sandini","year":"2019","unstructured":"Sandini M, Ruscic KJ, Ferrone CR, et al. Major complications independently increase long-term mortality after pancreatoduodenectomy for cancer. J Gastrointest Surg. 2019;23:1984\u201390.","journal-title":"J Gastrointest Surg."},{"key":"19739_CR14","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1097\/XCS.0000000000000499","volume":"236","author":"ZV Fong","year":"2023","unstructured":"Fong ZV, Verdugo FL, Fernandez-Del Castillo C, et al. Tolerability, attrition rates, and survival outcomes of neoadjuvant FOLFIRINOX for nonmetastatic pancreatic adenocarcinoma: intent-to-treat analysis. J Am Coll Surg. 2023;236:1126\u201336.","journal-title":"J Am Coll Surg."},{"key":"19739_CR15","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1002\/cncr.35535","volume":"130","author":"AN Martin","year":"2024","unstructured":"Martin AN, Chan NW, Cheung DC, Fong ZV. A guide to large data sets for population-based cancer research: strengths, limitations, and pitfalls. Cancer. 2024;130:3802\u201314.","journal-title":"Cancer."},{"key":"19739_CR16","first-page":"3","volume":"2020","author":"L Enewold","year":"2020","unstructured":"Enewold L, Parsons H, Zhao L, et al. Updated overview of the SEER-Medicare data: enhanced content and applications. J Natl Cancer Inst Monogr. 2020;2020:3\u201313.","journal-title":"J Natl Cancer Inst Monogr."},{"key":"19739_CR17","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/00005650-199308000-00006","volume":"31","author":"AL Potosky","year":"1993","unstructured":"Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732\u201348.","journal-title":"Med Care."},{"key":"19739_CR18","unstructured":"Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017."},{"key":"19739_CR19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1200\/JCO.2013.50.7657","volume":"32","author":"JW Valle","year":"2014","unstructured":"Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32:504\u201312.","journal-title":"J Clin Oncol."},{"key":"19739_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.hpb.2019.06.019","volume":"22","author":"TM Mackay","year":"2020","unstructured":"Mackay TM, Smits FJ, Roos D, et al. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. HPB Oxf. 2020;22:233\u201340.","journal-title":"HPB Oxf."},{"key":"19739_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12957-024-03393-7","volume":"22","author":"C Poiraud","year":"2024","unstructured":"Poiraud C, Lenne X, Bruandet A, et al. Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study. World J Surg Oncol. 2024;22:123.","journal-title":"World J Surg Oncol."},{"key":"19739_CR22","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11605-012-1938-y","volume":"16","author":"PJ Kneuertz","year":"2012","unstructured":"Kneuertz PJ, Pitt HA, Bilimoria KY, et al. Risk of morbidity and mortality following hepato-pancreato-biliary surgery. J Gastrointest Surg. 2012;16:1727\u201335.","journal-title":"J Gastrointest Surg."},{"key":"19739_CR23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1245\/s10434-015-4930-4","volume":"23","author":"T de Rooij","year":"2016","unstructured":"de Rooij T, Tol JA, van Eijck CH, et al. Outcomes of distal pancreatectomy for pancreatic ductal adenocarcinoma in the Netherlands: a nationwide retrospective analysis. Ann Surg Oncol. 2016;23:585\u201391.","journal-title":"Ann Surg Oncol."},{"key":"19739_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/cen.14168","volume":"92","author":"L Wu","year":"2020","unstructured":"Wu L, Nahm CB, Jamieson NB, et al. Risk factors for development of diabetes mellitus (type 3c) after partial pancreatectomy: a systematic review. Clin Endocrinol Oxf. 2020;92:396\u2013406.","journal-title":"Clin Endocrinol Oxf."},{"key":"19739_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/jso.26046","volume":"122","author":"CJR Schlick","year":"2020","unstructured":"Schlick CJR, Merkow RP, Yang AD, Bentrem DJ. Post-discharge venous thromboembolism after pancreatectomy for malignancy: predicting risk based on preoperative, intraoperative, and postoperative factors. J Surg Oncol. 2020;122:675\u201383.","journal-title":"J Surg Oncol."},{"key":"19739_CR26","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.surg.2015.10.028","volume":"159","author":"MT McMillan","year":"2016","unstructured":"McMillan MT, Christein JD, Callery MP, et al. Comparing the burden of pancreatic fistulas after pancreatoduodenectomy and distal pancreatectomy. Surgery. 2016;159:1013\u201322.","journal-title":"Surgery."},{"key":"19739_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/jhbp.934","volume":"28","author":"CB Nahm","year":"2021","unstructured":"Nahm CB, Alzaabi S, Sahni S, Gill AJ, Samra JS, Mittal A. Increased postoperative pancreatic fistula rate after distal pancreatectomy compared with pancreatoduodenectomy is attributable to a difference in acinar scores. J Hepatobiliary Pancreat Sci. 2021;28:533\u201341.","journal-title":"J Hepatobiliary Pancreat Sci."},{"key":"19739_CR28","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1097\/SLA.0000000000006250","volume":"279","author":"A Gikandi","year":"2024","unstructured":"Gikandi A, Hallet J, Koerkamp BG, et al. Distinguishing clinical from statistical significances in contemporary comparative effectiveness research. Ann Surg. 2024;279:907\u201312.","journal-title":"Ann Surg."},{"key":"19739_CR29","doi-asserted-by":"publisher","first-page":"e0173960","DOI":"10.1371\/journal.pone.0173960","volume":"12","author":"HW Kim","year":"2017","unstructured":"Kim HW, Lee JC, Lee J, Kim JW, Kim J, Hwang JH. Early versus delayed initiation of adjuvant treatment for pancreatic cancer. PLoS One. 2017;12:e0173960.","journal-title":"PLoS One."},{"key":"19739_CR30","doi-asserted-by":"publisher","first-page":"e199126","DOI":"10.1001\/jamanetworkopen.2019.9126","volume":"2","author":"SJ Ma","year":"2019","unstructured":"Ma SJ, Oladeru OT, Miccio JA, Iovoli AJ, Hermann GM, Singh AK. Association of timing of adjuvant therapy with survival in patients with resected stage I to II pancreatic cancer. JAMA Netw Open. 2019;2:e199126.","journal-title":"JAMA Netw Open."},{"key":"19739_CR31","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/SLA.0000000000005710","volume":"277","author":"AA Javed","year":"2023","unstructured":"Javed AA, Floortje van Oosten A, Habib JR, et al. A delay in adjuvant therapy is associated with worse prognosis only in patients with transitional circulating tumor cells after resection of pancreatic ductal adenocarcinoma. Ann Surg. 2023;277:866\u201372.","journal-title":"Ann Surg."},{"key":"19739_CR32","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.surg.2022.04.018","volume":"172","author":"A Hamad","year":"2022","unstructured":"Hamad A, Eskander MF, Shen C, et al. In search of lost time: delays in adjuvant therapy for pancreatic adenocarcinoma among under-resourced patient populations. Surgery. 2022;172:982\u20138.","journal-title":"Surgery."},{"key":"19739_CR33","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s40001-023-01572-y","volume":"28","author":"XH Li","year":"2023","unstructured":"Li XH, Zhou EL, Dong XY, et al. Adjuvant chemotherapy in pancreatic cancer at different AJCC stages: a propensity score-matching analysis. Eur J Med Res. 2023;28:606.","journal-title":"Eur J Med Res."},{"issue":"4 Suppl","key":"19739_CR34","doi-asserted-by":"publisher","first-page":"TPS630","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS630","volume":"40","author":"CD Lopez","year":"2022","unstructured":"Lopez CD, Kardosh A, Chen EY-S, et al. NeoOPTIMIZE: an open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine\/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable\/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2022;40(4 Suppl):TPS630\u2013TPS630.","journal-title":"J Clin Oncol."},{"key":"19739_CR35","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","volume":"160","author":"JL van Dam","year":"2022","unstructured":"van Dam JL, Janssen QP, Besselink MG, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer. 2022;160:140\u20139.","journal-title":"Eur J Cancer."},{"key":"19739_CR36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.annonc.2024.12.015","volume":"36","author":"E Rangelova","year":"2025","unstructured":"Rangelova E, Stoop TF, van Ramshorst TME, et al. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Ann Oncol. 2025;36:529\u201342.","journal-title":"Ann Oncol."},{"key":"19739_CR37","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1245\/s10434-018-6765-2","volume":"25","author":"DW Nelson","year":"2018","unstructured":"Nelson DW, Chang SC, Grunkemeier G, et al. Resectable distal pancreas cancer: time to reconsider the role of upfront surgery. Ann Surg Oncol. 2018;25:4012\u20139.","journal-title":"Ann Surg Oncol."},{"key":"19739_CR38","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1245\/s10434-019-08137-6","volume":"27","author":"S Lof","year":"2020","unstructured":"Lof S, Korrel M, van Hilst J, et al. Impact of neoadjuvant therapy in resected pancreatic ductal adenocarcinoma of the pancreatic body or tail on surgical and oncological outcome: a propensity score-matched multicenter study. Ann Surg Oncol. 2020;27:1986\u201396.","journal-title":"Ann Surg Oncol."},{"key":"19739_CR39","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/ije\/29.5.891","volume":"29","author":"S Schneeweiss","year":"2000","unstructured":"Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol. 2000;29:891\u20138.","journal-title":"Int J Epidemiol."},{"key":"19739_CR40","doi-asserted-by":"publisher","first-page":"e009952","DOI":"10.1136\/bmjopen-2015-009952","volume":"6","author":"B Khokhar","year":"2016","unstructured":"Khokhar B, Jette N, Metcalfe A, et al. Systematic review of validated case definitions for diabetes in ICD-9-coded and ICD-10-coded data in adult populations. BMJ Open. 2016;6:e009952.","journal-title":"BMJ Open."},{"key":"19739_CR41","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/dmrr.2260","volume":"28","author":"N Ewald","year":"2012","unstructured":"Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev. 2012;28:338\u201342.","journal-title":"Diabetes Metab Res Rev."},{"key":"19739_CR42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/XCS.0000000000001213","volume":"240","author":"PL Quinn","year":"2025","unstructured":"Quinn PL, Nikahd M, Saiyed S, et al. Surgical second opinion for pancreatic cancer patients. J Am Coll Surg. 2025;240:270\u20138.","journal-title":"J Am Coll Surg."},{"issue":"8 Suppl","key":"19739_CR43","first-page":"55","volume":"40","author":"JL Warren","year":"2002","unstructured":"Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 Suppl):55\u201361.","journal-title":"Med Care."}],"updated-by":[{"DOI":"10.1245\/s10434-026-20347-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000}}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19739-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19739-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19739-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:53:00Z","timestamp":1789667580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19739-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["19739"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19739-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1245\/s10434-026-20347-3","URL":"https:\/\/doi.org\/10.1245\/s10434-026-20347-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Chi-Fu Jeffrey Yang previously served on Astrazeneca and Genentech advisory boards. Chi-Fu Jeffrey Yang has received a grant from Astrazeneca and has received honoraria from Astrazeneca and Genentech. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}